Godfrey Financial Associates’s Amplify Weight Loss Drug & Treatment ETF THNR Stock Holding History

Godfrey Financial Associates’s Portfolio THNR Stock Details THNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.21K	Hold	203	–	–	﹤0.01%	543
2026 Q1	$4.98K	Buy	203 +2	+1%	+$51	﹤0.01%	526
2025 Q4	$5.07K	Buy	+201	New	+$4.94K	﹤0.01%	512

Other funds holding THNR

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Godfrey Financial Associates's THNR Position: Q2 2026 in Review

Godfrey Financial Associates held its Amplify Weight Loss Drug & Treatment ETF (THNR) position steady in Q2 2026 at 203 shares worth $5.21K. The position accounts for ﹤0.01% of the portfolio, ranked #543.

Godfrey Financial Associates first reported a position in THNR in Q4 2025 and has held it in 3 quarters since. 4 funds tracked by Wall St. Rank hold THNR as of Q2 2026.

Godfrey Financial Associates held 203 shares of Amplify Weight Loss Drug & Treatment ETF worth $5.21K as of Q2 2026.
Godfrey Financial Associates left its Amplify Weight Loss Drug & Treatment ETF share count unchanged in Q2 2026.
Amplify Weight Loss Drug & Treatment ETF made up ﹤0.01% of Godfrey Financial Associates's portfolio in Q2 2026, its #543 holding.
Godfrey Financial Associates first reported a position in Amplify Weight Loss Drug & Treatment ETF in Q4 2025 and has held it in 3 quarters since.
4 funds tracked by Wall St. Rank held Amplify Weight Loss Drug & Treatment ETF as of Q2 2026.

Based on Godfrey Financial Associates's 13F filing for Q2 2026, filed 11 Aug 2026.